Document:

Amendment No. 2 to Amended and Restated Credit Agreement

 Exhibit 10.8 
 AMENDMENT NO. 2 TO AMENDED AND RESTATED CREDIT AGREEMENT 
 THIS
AMENDMENT NO. 2 TO AMENDED AND RESTATED CREDIT AGREEMENT CREDIT AGREEMENT (this “Amendment”), dated as of December 22, 2010, is made by and among GILEAD SCIENCES, INC., a Delaware corporation (the
“Parent”), GILEAD BIOPHARMACEUTICS IRELAND CORPORATION, an Irish company (“Gilead Ireland”, Gilead Ireland together with the Parent are together referred to as the “Borrowers”, and each
individually, as a “Borrower”), BANK OF AMERICA, N.A., a national banking association organized and existing under the laws of the United States (“Bank of America”), in its capacity as administrative agent
for the Lenders (in such capacity, the “Administrative Agent”), and each of the Lenders signatory hereto. 

W I T N E S S E T H: 
 WHEREAS, the Borrowers, Bank of America, as Administrative Agent, Swing Line Lender and L/C Issuer, and the Lenders have entered into that Credit Agreement, dated as of December 18, 2007 (as
previously amended, as hereby amended and as from time to time hereafter further amended, modified, supplemented, restated, or amended and restated, the “Credit Agreement”; capitalized terms used in this Amendment not otherwise
defined herein shall have the respective meanings given thereto in the Credit Agreement), pursuant to which the Lenders have made available to Borrower a revolving credit facility with a swing line sublimit and a letter of credit sublimit;

 WHEREAS, as a condition to making the revolving credit facility available to the Borrower the Lenders have required
that the Parent guarantee payment of the Obligations of Gilead Ireland; 
 WHEREAS, the Borrowers have requested
amendments to certain provisions of the Credit Agreement as set forth in Section 1 below, and 
 WHEREAS, the
Administrative Agent and the Lenders signatory hereto are willing to effect such waivers, consents and amendments, in each case as set forth below pursuant to the terms and conditions contained in this Amendment. 

NOW, THEREFORE, in consideration of the premises and further valuable consideration, the receipt and sufficiency of which is
hereby acknowledged, the parties hereto agree as follows: 
 1. Amendments to Credit Agreement. Subject to the terms and
conditions set forth herein, the Credit Agreement is hereby amended as follows: 
  

	 	(a)	Section 2.03(a)(i) is hereby amended by inserting “or extend” in the fifth line thereof immediately after “amend” and before
“Letters of Credit”. 

  

	 	(b)	Section 2.03(a)(ii)(A) is hereby amended by inserting (i) “subject to Section 2.03(b)(iv),” in the first line thereof immediately
after “(A)” and (ii) “or extension” in the second line thereof immediately after “renewal”. 

	 	(c)	A new clause (iv) is added to Section 2.03(b) which reads as follows: 

(iv) If a Borrower so requests in any applicable Letter of Credit Application, the L/C Issuer may, in its sole discretion,
agree to issue a Letter of Credit that has automatic extension provisions (each, an “Auto-Extension Letter of Credit”); provided that any such Auto-Extension Letter of Credit must permit the L/C Issuer to prevent any
such extension at least once in each twelve-month period (commencing with the date of issuance of such Letter of Credit) by giving prior notice to the beneficiary thereof not later than a day (the “Non-Extension Notice Date”) in
each such twelve-month period to be agreed upon at the time such Letter of Credit is issued. Unless otherwise directed by the L/C Issuer, the applicable Borrower shall not be required to make a specific request to the L/C Issuer for any such
automatic extension. Once an Auto-Extension Letter of Credit has been issued, the Lenders shall be deemed to have authorized (but may not require) the L/C Issuer to permit the extension of such Letter of Credit at any time to an expiry date not
later than the Letter of Credit Expiration Date; provided, however, that the L/C Issuer shall not permit any such extension if (A) the L/C Issuer has determined that it would not be permitted, or would have no obligation, at such
time to issue such Letter of Credit in its revised form (as extended) under the terms hereof (by reason of the provisions of clause (ii) or (iii) of Section 2.03(a) or otherwise), or (B) it has received notice (which may
be by telephone or in writing) on or before the day that is seven Business Days before the Non-Extension Notice Date (1) from the Administrative Agent that the Required Lenders have elected not to permit such extension or (2) from the
Administrative Agent, any Lender or the applicable Borrower that one or more of the applicable conditions specified in Section 4.02 is not then satisfied, and in each such case directing the L/C Issuer not to permit such extension;
provided, however, that the parties agrees that clauses (A) and (B) above set forth the only circumstances under which the L/C Issuer may not permit any such extension. 

 

	 	(d)	Section 7.09 is deleted in its entirety and the following is inserted in lieu thereof. 

7.09 Burdensome Agreements. Enter into any contractual obligation (other than this Agreement or any other Loan
Document) that (a) limits the ability (i) of any Subsidiary to make Restricted Payments to either Borrower or otherwise transfer property to either Borrower, (ii) of any Subsidiary to Guarantee the Indebtedness of the Borrowers or
(iii) of the Borrowers or any Subsidiary to create, incur, assume or suffer to exist Liens on property of such Person; provided, however, that the foregoing shall not apply to (A) restrictions and conditions existing on
Second Amendment Effective Date (or any extension, renewal, amendment or modification thereof), (B) any contractual obligation of a Person which becomes a Subsidiary after the Closing Date; provided that such contractual obligation is
only binding upon such Subsidiary and such contractual obligation was in existence at the time such Person becomes a Subsidiary, (but shall apply to any extension or renewal of, or any amendment or modification expanding the scope of, any such
restriction or condition), (C) restrictions and conditions imposed by any agreement or document governing or evidencing any other Indebtedness, Swap Contract or other obligation of a Borrower or any Subsidiary permitted hereunder, so

  
 2 

 
long as such documentation does not contain any covenant expressly limiting the ability of either Borrower or its Subsidiaries to enter into contractual obligations of the type described in the
foregoing clauses (i) through (iii) that is materially more restrictive on the Borrowers and its subsidiaries than this Section 7.09, (D) restrictions in such Person’s organizational documents or
pursuant to any joint venture agreement or equity holder’s agreement, (E) any restrictions with respect to a Subsidiary imposed pursuant to an agreement which has been entered into in connection with a Disposition, (F) any negative
pledge incurred or provided in favor of any holder of Indebtedness permitted hereunder solely to the extent any such negative pledge relates to the property financed by or the subject of such Indebtedness, (G) any negative pledge incurred or
provided in favor a financial institution with respect to deposit or other account pooling agreements, cash management agreements and similar arrangements, so long as such negative pledge relates only to the deposit accounts subject to such
agreement, and (z) apply to customary provisions in leases and other contracts restricting the assignment, pledge or mortgage thereof. 
 2. Effectiveness; Conditions Precedent. The effectiveness of this Amendment and the amendments to the Credit Agreement herein provided are subject to the satisfaction of the following conditions
precedent (the first date on which all such conditions have been satisfied shall be referred to as the “Second Amendment Effective Date”): 
  

	 	(a)	the Administrative Agent shall have received each of the following documents or instruments in form and substance reasonably acceptable to the Administrative Agent:

  

	 	(i)	counterparts of this Amendment, duly executed by each of the Borrowers, the Parent in its capacity as a guarantor, the Administrative Agent, and the Required Lenders;
and 

  

	 	(ii)	such other certificates, instruments and documents as the Administrative Agent shall reasonably request; 

 

	 	(b)	the Borrowers shall have paid to each Lender that signs this Amendment on or before the Second Amendment Effective Date a fee of $10,000, which fee shall be fully
earned and due on the Second Amendment Effective Date and shall be nonrefundable; and 

  

	 	(c)	unless waived by the Administrative Agent, all fees and expenses payable to the Administrative Agent and the Lenders (including the reasonable fees and expenses of
counsel to the Administrative Agent to the extent invoiced prior to the date hereof) estimated to date shall have been paid in full (without prejudice to final settling of accounts for such fees and expenses). 

  
 3 

 3. Consent and Confirmation of the Parent. The Parent hereby consents, acknowledges
and agrees to the amendments set forth herein and hereby confirms and ratifies in all respects the Parent Guaranty Agreement (including without limitation the continuation of the Parent’s payment and performance obligations thereunder upon and
after the effectiveness of this Amendment and the amendments contemplated hereby) and the enforceability of the Parent Guaranty against the Parent in accordance with its terms. 

4. Representations and Warranties. In order to induce the Administrative Agent and the Lenders to enter into this Amendment, each
Borrower represents and warrants to the Administrative Agent and the Lenders as follows: 
  

	 	(a)	The representations and warranties contained in Article V of the Credit Agreement or any other Loan Documents, or which are contained in any document furnished
at any time under or in connection with the Credit Agreement or such other Loan Document, are true and correct in all material respects on and as of the date hereof, (i) except to the extent that such representations and warranties specifically
refer to an earlier date, in which case they are true and correct in all material respects as of such earlier date, and (ii) except that the representations and warranties contained in subsections (a) and (b) of
Section 5.05 of the Credit Agreement shall be deemed to refer to the most recent statements furnished pursuant to clauses (a) and (b), respectively, of Section 6.01 of the Credit Agreement;

  

	 	(b)	The Persons appearing as guarantor on the signature pages to this Amendment constitute all Persons who are required to be guarantors pursuant to the terms of the Credit
Agreement and the other Loan Documents; 

  

	 	(c)	This Amendment has been duly authorized, executed and delivered by the Borrowers and the Parent, as guarantor, and constitutes a legal, valid and binding obligation of
such parties, except as may be limited by general principles of equity or by the effect of any applicable bankruptcy, insolvency, reorganization, moratorium or similar law affecting creditors’ rights generally; and 

 

	 	(d)	After giving effect to this Amendment, no Default or Event of Default has occurred and is continuing. 

5. Release. In consideration of the Administrative Agent and the Required Lenders entering into this Amendment on behalf of the
Lenders, the Borrowers hereby release the Administrative Agent, the L/C Issuer, each of the Lenders, and the Administrative Agent’s, the L/C Issuer’s and each of the Lender’s respective officers, employees, representatives, agents,
counsel and directors from any and all actions, causes of action, claims, demands, damages and liabilities of whatever kind or nature, in law or in equity, now known or unknown, suspected or unsuspected to the extent that any of the foregoing arises
from any action or failure to act solely in connection with the Loan Documents on or prior to the date hereof. 
 6. Entire
Agreement. This Amendment, together with the Loan Documents (collectively, the “Relevant Documents”), sets forth the entire understanding and agreement of 

  
 4 

 
the parties hereto in relation to the subject matter hereof and supersedes any prior negotiations and agreements among the parties relating to such subject matter. No promise, condition,
representation or warranty, express or implied, not set forth in the Relevant Documents shall bind any party hereto, and no such party has relied on any such promise, condition, representation or warranty. Each of the parties hereto acknowledges
that, except as otherwise expressly stated in the Relevant Documents, no representations, warranties or commitments, express or implied, have been made by any party to the other in relation to the subject matter hereof or thereof. None of the terms
or conditions of this Amendment may be changed, modified, waived or canceled orally or otherwise, except in writing and in accordance with Section 10.01 of the Credit Agreement. 

7. Full Force and Effect of Amendment. Except as hereby specifically amended, modified or supplemented, the Credit Agreement and
all other Loan Documents are hereby confirmed and ratified in all respects and shall be and remain in full force and effect according to their respective terms. 
 8. Counterparts. This Amendment may be executed in any number of counterparts, each of which shall be deemed an original as against any party whose signature appears thereon, and all of which shall
together constitute one and the same instrument. Delivery of an executed counterpart of a signature page of this Amendment by telecopy, facsimile or other electronic transmission (including .PDF) shall be effective as delivery of a manually executed
counterpart of this Amendment. 
 9. Governing Law. This Amendment shall in all respects be governed by, and construed in
accordance with, the laws of the State of New York. 
 10. Enforceability. Should any one or more of the provisions of
this Amendment be determined to be illegal or unenforceable as to one or more of the parties hereto, all other provisions nevertheless shall remain effective and binding on the parties hereto. 

11. References. All references in any of the Loan Documents to the “Credit Agreement” shall mean the Credit Agreement,
as amended hereby. 
 12. Successors and Assigns. This Amendment shall be binding upon and inure to the benefit of the
Borrowers, the Administrative Agent, the Lenders and their respective successors and assignees to the extent such assignees are permitted assignees as provided in Section 10.06 of the Credit Agreement. 

[Signature pages follow.] 

  
 5 

 IN WITNESS WHEREOF, the parties hereto have caused this instrument to be made,
executed and delivered by their duly authorized officers as of the day and year first above written. 
  

			
	GILEAD SCIENCES, INC., as a Borrower
		
	By:	 	 /s/ John F. Milligan

			
	Name:	 	John F. Milligan, PhD
	Title:	 	President and Chief Operating Officer
	
	GILEAD BIOPHARMACEUTICS IRELAND CORPORATION, as a Borrower

			
		
	By:	 	 /s/ John F. Milligan

			
	Name:	 	John F. Milligan, PhD
	Title:	 	Director

			
		
	By:	 	 /s/ Gregg H. Alton

			
	Name:	 	Gregg H. Alton
	Title:	 	Director
	
	GUARANTOR:

			
	
	GILEAD SCIENCES, INC., as a guarantor of Gilead Ireland
		
	By:	 	 /S/ John F. Milligan

			
	Name:	 	John F. Milligan, PhD
	Title:	 	President and Chief Operating Officer

  
 Gilead
Sciences, Inc. and Gilead Biopharmaceutics Ireland Corporation 
 Amendment No. 2 to Amended and Restated Credit Agreement

 
			
	ADMINISTRATIVE AGENT:
	
	BANK OF AMERICA, N.A., as Administrative   Agent

			
		
	By:	 	 /s/ Dora A. Brown

			
	Name:	 	 Dora A. Brown
	Title:	 	Vice President

  
 Gilead
Sciences, Inc. and Gilead Biopharmaceutics Ireland Corporation 
 Amendment No. 2 to Amended and Restated Credit Agreement

 
			
	 BANK OF AMERICA, N.A., as a Lender, L/C
 Issuer and Swing Line Lender

			
		
	By:	 	 /s/ John C. Plecque

			
	Name:	 	 John C. Plecque
	Title:	 	Senior Vice President

  
 Gilead
Sciences, Inc. and Gilead Biopharmaceutics Ireland Corporation 
 Amendment No. 2 to Amended and Restated Credit Agreement

 
			
	 THE ROYAL BANK OF SCOTLAND N.V. 
 (FORMERLY ABN AMRO BANK N.V.), as a Lender

			
		
	By:	 	 /s/ William McGinty

			
	Name:	 	 William McGinty
	Title:	 	Director

  
 Gilead
Sciences, Inc. and Gilead Biopharmaceutics Ireland Corporation 
 Amendment No. 2 to Amended and Restated Credit Agreement

 
			
	CITIBANK, N.A., as a Lender

			
		
	By:	 	 /s/ Henry H. Schwake

			
	Name:	 	  Henry H. Schwake

			
	Title:	 	 Managing Director

  
 Gilead
Sciences, Inc. and Gilead Biopharmaceutics Ireland Corporation 
 Amendment No. 2 to Amended and Restated Credit Agreement

 
			
	DEUTSCHE BANK TRUST COMPANY AMERICAS, as a Lender

			
		
	By:	 	 /s/ Frederick W. Laird

			
	Name: 	 	 Frederick W. Laird

			
	Title:	 	 Managing Director

			
		
	By:	 	 /s/ Ming K. Chu

			
	Name: 	 	 Ming K. Chu

			
	Title:	 	 Vice President

  
 Gilead
Sciences, Inc. and Gilead Biopharmaceutics Ireland Corporation 
 Amendment No. 2 to Amended and Restated Credit Agreement

 
			
	WELLS FARGO BANK, N.A., as a Lender

			
		
	By:	 	 /s/ Matthew Burke

			
	Name: 	 	 Matthew Burke

			
	Title:	 	 Vice President

  
 Gilead
Sciences, Inc. and Gilead Biopharmaceutics Ireland Corporation 
 Amendment No. 2 to Amended and Restated Credit Agreement

 
			
	 MIZUHO CORPORATE BANK, LTD., as a
 Lender

			
		
	By:	 	 /s/ Bertram H. Tang

			
	Name: 	 	 Bertram H. Tang

			
	Title:	 	 Authorized Signatory

  
 Gilead
Sciences, Inc. and Gilead Biopharmaceutics Ireland Corporation 
 Amendment No. 2 to Amended and Restated Credit Agreement

 
			
	KEYBANK NATIONAL ASSOCIATION, as a Lender

			
		
	By:	 	 /s/ Thomas J. Purcell

			
	Name: 	 	 Thomas J. Purcell

			
	Title:	 	 Senior Vice President

  
 Gilead
Sciences, Inc. and Gilead Biopharmaceutics Ireland Corporation 
 Amendment No. 2 to Amended and Restated Credit Agreement

 
			
	BARCLAYS BANK PLC, as a Lender

			
		
	By:	 	 /s/ David Barton

			
	Name: 	 	 David Barton

			
	Title:	 	 Director

  
 Gilead
Sciences, Inc. and Gilead Biopharmaceutics Ireland Corporation 
 Amendment No. 2 to Amended and Restated Credit Agreement

 
			
	JPMORGAN CHASE BANK, N.A., as a Lender

			
		
	By:	 	 /s/ Vanessa Chiu

			
	Name: 	 	 Vanessa Chiu

			
	Title:	 	 Executive Director

  
 Gilead
Sciences, Inc. and Gilead Biopharmaceutics Ireland Corporation 
 Amendment No. 2 to Amended and Restated Credit Agreement

 
			
	MORGAN STANLEY BANK, as a Lender

			
		
	By:	 	 /s/ Agata Marczak

			
	Name: 	 	 Agata Marczak

			
	Title:	 	 Authorized Signatory

  
 Gilead
Sciences, Inc. and Gilead Biopharmaceutics Ireland Corporation 
 Amendment No. 2 to Amended and Restated Credit Agreement

 
			
	GOLDMAN SACHS BANK USA, as a Lender

			
		
	By:	 	 /s/ Lauren Day

			
	Name: 	 	 Lauren Day

			
	Title:	 	 Authorized Signatory

  
 Gilead
Sciences, Inc. and Gilead Biopharmaceutics Ireland Corporation 
 Amendment No. 2 to Amended and Restated Credit Agreement

 
			
	CREDIT SUISSE AG, Cayman Islands Branch [formerly CREDIT SUISSE, Cayman Islands Branch], as a Lender

			
		
	By:	 	 /s/ Ari Bruger

			
	Name: 	 	 Ari Bruger

			
	Title:	 	 Vice President

			
		
	By:	 	 /s/ Rahul Parmer

			
	Name: 	 	 Rahul Parmer

			
	Title:	 	 Associate

  
 Gilead
Sciences, Inc. and Gilead Biopharmaceutics Ireland Corporation 
 Amendment No. 2 to Amended and Restated Credit Agreement

 
			
	U.S. BANK NATIONAL ASSOCIATION, as a Lender

			
		
	By:	 	 /s/ David C. Mruk

			
	Name: 	 	 David C. Mruk

			
	Title:	 	 Vice President

  
 Gilead
Sciences, Inc. and Gilead Biopharmaceutics Ireland Corporation 
 Amendment No. 2 to Amended and Restated Credit Agreement

 
			
	 HSBC BANK USA, NATIONAL
 ASSOCIATION, as a Lender

			
		
	By:	 	 /s/ Jason A. Huck

			
	Name:	 	 Jason Huck

			
	Title:	 	 Vice President

  
 Gilead
Sciences, Inc. and Gilead Biopharmaceutics Ireland Corporation 
 Amendment No. 2 to Amended and Restated Credit Agreement

 
			
	INTESA SANPAOLO S.P.A., as a Lender

			
		
	By:	 	 /s/ Luca Sacchi

			
	Name: 	 	 Lucca Sacchi

			
	Title:	 	 Vice President

			
		
	By:	 	 /s/ Frank Maffei

			
	Name: 	 	 Frank Maffei

			
	Title:	 	 Vice President

  
 Gilead
Sciences, Inc. and Gilead Biopharmaceutics Ireland Corporation 
 Amendment No. 2 to Amended and Restated Credit AgreementTenofovir Disoproxil Fumarate Manufacturing Supply Agreement

 Exhibit 10.90 
 GILEAD SCIENCES LIMITED.-AMPAC FINE CHEMICALS LLC 
 TENOFOVIR DISOPROXIL
FUMARATE MANUFACTURING SUPPLY AGREEMENT 
 THE PARTIES HEREBY ACKNOWLEDGE
AND AGREE THE FOLLOWING: 
 THIS SUPPLY AGREEMENT (“Agreement”) is
entered into as of November 3, 2010 (“Effective Date”), by and between Ampac Fine Chemicals LLC, a California limited liability company (“AFC”) having its principal place of business at Highway 50 &
Hazel Avenue, Rancho Cordova, CA 95670, and a mailing address of P.O. Box 1718, Rancho Cordova, CA 95741, and Gilead Sciences Limited, an Irish limited company (“GSL”), having its principal place of business at Unit 13, Stillorgan
Industrial Park, Blackrock, Co. Dublin, Ireland. AFC and GSL may be referred to individually as a “Party” and collectively as the “Parties” in this Agreement. 

WHEREAS, AFC is a known manufacturer of active pharmaceutical ingredients with expertise in cGMP manufacturing, and GSL and its designees
manufacture and market pharmaceutical products for human use. 
 WHEREAS, AFC and GSL desire to establish mutually agreeable
terms for the commercial supply of bulk tenofovir disoproxil fumarate (“Product”) as an active pharmaceutical ingredient by AFC to GSL. 
 NOW, THEREFORE, in consideration of (i) AFC’s agreement to manufacture and supply Product to GSL for the monetary amounts set forth in this Agreement; (ii) the promises, covenants,
agreements and other valuable consideration hereinafter set forth, and intending to be legally bound, the Parties hereby agree: 
 1.
AGREEMENT ACCEPTANCE: AFC has read and understands these terms and conditions set forth in this Agreement (these “terms”) and understands that AFC’s written acceptance or delivery of any Product under these terms shall
constitute AFC’s acceptance of these terms. All terms and conditions proposed by AFC which are different from or in addition to these terms and are not agreed to in writing by GSL are expressly rejected by GSL, and shall not become a part of
these terms. GSL has read and understands these terms and shall purchase the Product manufactured by AFC and pay for the supply of the Product in accordance with the terms and provisions of these terms. Any modifications to these terms shall, prior
to their implementation, be mutually agreed upon by the Parties hereto and shall be made in accordance with Section 28. 
 Neither the
General Sales Conditions of AFC nor the General Purchase Conditions of GSL shall apply to the supply of the Product by AFC to GSL pursuant to these terms. 
 2. TERM: The term of this Agreement shall begin as of the Effective Date, and shall remain in effect until December 31, 2013 (the “Initial Term”) unless earlier terminated
according to Section 13 “Termination” of this Agreement. 
  

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT
TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 

 3. SUPPLY: During the term of this Agreement, AFC will manufacture Product for GSL for use in
manufacture of Finished Product (as defined in Section 4 below). During the term of this Agreement, AFC is obligated to manufacture Product at the location and in the quantities set forth herein. AFC will not manufacture or supply Product to
any person or entity other than GSL without GSL’s prior written consent. 
  

	 	a)	Facility: AFC will manufacture the Product for GSL only at its facility located at Rancho Cordova, CA, or such other facilities as the Parties agree to in
writing (collectively, the “Facility”). GSL has inspected the Facility and has acknowledged, based upon information in its possession as of the Effective Date, that the Facility appears to be appropriate for the purposes of
manufacturing the Products. 

  

	 	b)	Minimum Quantities: During the Initial Term and any renewal term GSL will purchase and AFC will deliver at least the quantities of Product set forth in Exhibit
A. Failure in any year by GSL to purchase the required quantities will result in [*] an amount equal to the [*], the invoice for which will be [*], and such invoice shall be [*]. For clarity, GSL’s
failure to satisfy minimum purchase requirements due to Regulatory Terminations (as defined in Section 13(c) below) shall not be deemed to be breaches by GSL of GSL’s obligations under this Section 3(b). 

 

	 	c)	Forecasting: Prior to [*] of [*], GSL shall provide to AFC a [*] for the [*]. Such GSL Purchase Order shall detail the [*],
and shall be [*]. 

  

	 	d)	Acceptance: AFC will respond in writing to each purchase order received from GSL (“GSL Purchase Order”) within [*] calendar days of
receipt. The response shall include AFC’s inability to comply with, or confirmation of the delivery dates and quantities set forth in the GSL Purchase Order. 

 

	 	e)	Failure to Supply: If AFC is unable to supply sufficient quantities of the Product to meet its minimum obligations under Section 3(b), or should either
Party perceive that a shortfall (according to the definition of shortfall in Section 3(f)) in delivery of Product by AFC is likely to occur for any reason, the Parties will [*]. GSL will have the right [*] or [*].
Any quantities [*] to meet such a shortfall shall be [*]. If GSL must [*], AFC shall be liable for [*]. Repeated shortfalls may be considered a material breach of this Agreement, as described in Section 13 of this
Agreement. 

  

	 	f)	Delay: If release and/or shipment of any quantity is delayed after AFC has accepted an order, through the fault of AFC, by more than [*] days
[*], the quantity shall be considered a shortfall, and treated as above in Section 3(e). If such delay is caused by the fault of GSL, GSL will make [*] to remediate the fault [*], however, after ([*]) days
from the date of expected release and/or shipment, AFC shall be entitled to issue the relevant invoice(s) in any case. 

  

	 	g)	 Successful Close-out: GSL acknowledges that AFC received a Warning Letter from

  
 [*] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 

	 	 
the FDA on June 25, 2010 in association with a Form FDA 483 received in February 2010 (the “Warning Letter”). AFC agrees to use its reasonable best efforts to
remediate the deficiencies identified by the FDA in a timely manner. AFC will either (i) provide Gilead with a copy of the close-out letter received from the FDA following the FDA’s re-inspection indicating the FDA’s satisfaction with
the corrective actions taken by AFC in response to the Warning Letter, or (ii) following such re-inspection by the FDA provide Gilead with a written certification signed by a senior officer of AFC that it has satisfied the concerns raised by
the FDA pursuant to the Warning Letter. Once Gilead has received either a copy of such close-out letter or such written certification, Gilead will acknowledge such event as a “Successful Close-out”. If a Successful
Close-out is not achieved by AFC following the FDA’s re-inspection, GSL will have the option to issue a Regulatory Termination in accordance with Section 13(c) below with the exception that the thirty (30) day notice period
shall not apply, and at GSL’s discretion this may be considered an Adverse Event per Section 17. 

 4. GOOD
MANUFACTURING PRACTICES: AFC expressly warrants that all Product covered by these terms have been manufactured in accordance with current good manufacturing practices (“cGMP”) as established by the United States Food and Drug
Administration (the “FDA”) for the manufacture of pharmaceutical materials, as well as other applicable rules and regulations of the FDA and other governmental or regulatory agencies of United States or other countries where
finished pharmaceutical products of GSL incorporating the Product (collectively, the “Finished Products”) are marketed with jurisdiction over the manufacture, use, or sale of Product, as then in effect. Each
party shall promptly notify the other of any new instructions or specifications required by the FDA, the Federal Food, Drug and Cosmetic Act, the Federal Public Health Service Act or other applicable regulations of the United States and/or other
countries where the Finished Products are marketed, and shall confer with each other with respect to the best means to comply with such requirements and shall allocate any costs of implementing such changes on an equitable basis. Upon written
request of GSL, AFC will permit representatives of GSL to observe such manufacture, or any government inspection of AFC’s manufacturing process for the Products covered by these terms, at mutually agreeable times and AFC shall permit GSL to
inspect copies of AFC’s manufacturing records, including its batch records, for the purposes of assuring product quality and compliance with agreed-upon manufacturing procedures. 
 5. MANUFACTURING PROCESS: GSL shall make available to AFC, [*], all such know-how, information, and technical assistance if needed by AFC so as to allow AFC to manufacture Product
with utmost efficiency and to the standard of GSL as will be more precisely described by GSL in writing to AFC before the start of manufacturing of the Product. AFC shall manufacture the Product in conformance with the relevant specifications, as
then in effect (the “Specifications”) and according to the manufacturing process description as set forth in the Gilead Sciences Tenofovir DF Contract Manufacturing Manual dated June 6, 2000, and as thereafter amended (the
“Contract Manufacturing Manual”). 

  
 [*] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 

 6. RAW MATERIALS: Raw materials used in the manufacture of Product will conform to the specifications
set forth in the Contract Manufacturing Manual (the “Raw Material Specifications”) and such conformance will be verified in accordance with the testing standards and procedures specified therein. AFC agrees that it will facilitate
changes to the Raw Material Specifications that are necessary or appropriate in light of FDA or other regulatory requirements. AFC shall not be liable hereunder if the raw materials meet the Raw Material Specifications and the Product fails to meet
the Specifications because the Raw Material Specifications are inadequate. 
 7. CHANGE IN MANUFACTURING PROCESS: AFC shall obtain
GSL’s prior written approval, per the Quality Agreement (August 1, 2010), before implementing any planned change in the materials, equipment, process, or procedures used to manufacture the Product that would constitute a major change under
cGMP, or that would constitute noncompliance with the manufacturing process set forth in the Contract Manufacturing Manual. AFC shall disclose all proposed changes in such manufacturing materials, equipment, process, or procedure to GSL at a level
sufficient to allow GSL to practice such changed manufacturing process. GSL shall notify AFC of any change in the materials, equipment, process, analytical methods, specifications, or procedures to be used in the manufacture of the Product in
writing, by means of timely updates to the Contract Manufacturing Manual, identical copies of which reside at AFC and GSL. AFC shall provide GSL with an authentic copy of the current master batch record for the preparation of the Product. The cost
of implementing any amendment or change of whatever nature to the procedures described in the Contract Manufacturing Manual, as well as any extra costs resulting from the implementation of such change, shall be borne by [*]. However, the
Parties recognize the pricing agreed in Exhibit A reflect implementation of the process developed by AFC and GSL during 2009-2010, which, at the time of this agreement, is not represented in the Contract Manufacturing Manual. 

8. PROCESS IMPROVEMENTS: 
  

	 	a)	[*] agrees to communicate to [*] any idea and substantial improvement made by [*] arising from [*] under the following conditions:
(i) all rights and title to improvements (patented or unpatentable) which are related to the [*] shall be assigned to [*], which shall have only the right to utilize such improvements in the manufacture of the Product;
(ii) all rights and title to improvements (patented or unpatentable) which apply to the [*], and provided that [*], is not contained in said improvements, shall be assigned to [*], which shall have only the right to utilize
such improvements in the process of the Product; (iii) a royalty-free worldwide exclusive license [*] shall be granted by [*] to [*] for improvements (patented or unpatentable) related to said processing [*];
(iv) in the event that [*] contracts out the manufacture of the Product to any third party, any improvement made by [*] hereunder may be disclosed to such contract manufacturer but rights to use the same shall be restricted to the
manufacture of the Product and the Parties hereto will [*]. 

  

	 	b)	 The Parties recognize the process changes under development by AFC and GSL for piloting and validation in 2010. All rights to said improvement shall be
passed to [*], in 

  
 [*] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 

	 	 
accordance with the provisions of Section 8(a), (i) through (iii), above. The Parties confirm no further remuneration shall be sought by [*] under Section 8(a)(iv)
above. AFC will produce a development report describing such revised process to be provided to GSL prior to commercial scale validation of such process. Further, AFC shall provide to GSL necessary assistance in support of technology transfer to one
Gilead Sciences, Inc.-owned facility, which may include teleconferences, meetings, and chemistry support during the initial commercial campaign. 

 9. QUALITY CONTROL SAMPLE AND DOCUMENTATION: Manufacture of the Product shall at all times be in strict conformance with the Specifications and such conformance will be verified in accordance with
the testing procedures, specified herein. Prior to the delivery of any batch of Product, AFC shall provide GSL with (i) a quality control sample of such batch to be held by GSL for analytical reference, (ii) written confirmation that the
batch records for such batch have been reviewed and approved by AFC’s quality assurance unit (Certificate of Compliance), and (iii) a Certificate of Analysis confirming that such batch meets Specifications. No delivery of the Product shall
be made until GSL accepts the material in accordance with the provisions of Paragraph 10. 
 10. BATCH ACCEPTANCE AND REJECTION: GSL
shall have the right without penalty to cancel delivery of an entire batch of Product at any time within [*] days after receipt of the applicable Certificate of Compliance and Certificate of Analysis (the “Acceptance Period”). Title
and risk of loss for each batch of Product shall pass to GSL upon [*]. If no such notice of rejection is received, GSL shall be deemed to have accepted the batch of Product upon the expiration of Acceptance Period. Either GSL’s written
acceptance of the batch or expiration of the Acceptance Period shall result in GSL assuming title and risk of loss for related batch. AFC shall be authorized to make delivery of the full batch upon GSL’s acceptance of the batch, pending receipt
of specific delivery instructions from GSL. AFC represents and warrants that the Product delivered to the destination specified by GSL shall comply with the Specifications for the Product. Any contestation of the quantity of Product delivered to the
destination specified by GSL or the related documentation must be made in writing to AFC within [*] days from receipt thereof by GSL or an agent of GSL. GSL and AFC shall [*] or [*], as appropriate. After notice of rejection is
given, GSL shall cooperate with AFC in determining whether rejection is necessary or justified. AFC will evaluate process issues and other reasons for such non-compliance. AFC shall notify GSL as promptly as reasonably possible whether it accepts
GSL’s basis for any rejection. In the event that such contestation of quality by GSL is not accepted by AFC, a sample of the contested batch sealed by AFC in compliance with applicable regulations shall be submitted by AFC to an independent
laboratory, acceptable to GSL, and the check assay of said laboratory shall be accepted by the two Parties as final and binding. The cost of said analysis made by the laboratory shall be borne by the failing party. Whether or not AFC accepts
GSL’s basis for rejection, AFC shall use reasonable efforts at GSL’s request to replace such rejected Product. If the third party laboratory determines that the batch meets the Specifications, GSL guarantees to purchase that batch at the
agreed-upon price, irrespective of whether AFC has already replaced it. GSL may not destroy any batch of Product until it receives 

  
 [*] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 

 
written notification from AFC that AFC does not dispute that the batch fails to meet Specifications and that AFC does not request return of the Product. Upon authorization from AFC to do so, GSL
shall destroy the Product received in the rejected delivery promptly at AFC’s cost and provide AFC with certification of such destruction. GSL shall, upon receipt of AFC’s request for return, promptly return said Product or quality control
sample to AFC, at AFC’s cost. At its election, GSL may treat any rejected batch of Product as [*], until and unless it is finally determined that the batch complied with the warranties in Section 14. 

11. QUANTITY AND PRICE: The quantity, schedule, and purchase price of Product covered by these terms will be provided in separate GSL Purchase
Orders. These terms shall apply to all GSL Purchase Orders written while these terms are in effect. All GSL Purchase Orders covered by this agreement shall reference this agreement by its effective date. The negotiated price for the Product shall
include up to [*] storage at AFC’s facility, according to Paragraph 25. 
 12. DELIVERY, SHIPPING, BILLING AND PAYMENT: GSL
will provide AFC with an estimated delivery date for each batch at the end of the Acceptance Period or at the time of acceptance of the batch, if earlier. GSL will then have [*] days to schedule processing of the Product with its contracted
formulation and encapsulation facility and provide specific delivery instructions to AFC. If specific delivery instructions are not provided to AFC within the [*] day period, the “Warehousing” provision included under Paragraph 25
will be considered in effect and GSL will have [*] days to provide the written request and other information required to be provided to AFC under that provision. AFC will package and load the Product in accordance with AFC’s customary
practices for pharmaceutical compounds, unless otherwise specified by GSL. Unless otherwise agreed to by the Parties in writing, all shipments shall be shipped [*] pursuant to written instructions provided by GSL to AFC. The quantity of
Product made available to GSL’s carrier shall be the same amount as invoiced by AFC, unless AFC is otherwise directed in writing by GSL. AFC shall maintain appropriate insurance as far as AFC’s custodial responsibilities with respect to
the Product temporarily held at AFC’s facility and owned by GSL. [*] is responsible for selecting the carrier that will transport the Product. GSL will maintain the appropriate insurance coverage for Product that it has accepted,
including any Product owned by GSL held temporarily or stored at AFC’s facility. Within [*] calendar days of receipt of such shipping instructions from GSL, AFC shall ship the invoiced amount of Product to its destination. All invoices
from AFC to GSL covering Product shipped to GSL shall be stated, and all payments to AFC by GSL shall be made, in [*]. The invoices will be issued upon completion of the batches and issuance of the Certificate of Compliance and Certificate of
Analysis for each batch in accordance with Section 9. AFC’s invoice shall be paid by GSL not later than [*] days following the latest of (i) the receipt of the applicable invoice, (ii) expiration of the Acceptance Period,
and (iii) the receipt of the Certificate of Analysis and Certificate of Compliance. Any invoiced amount which is not paid within [*] days of its due date shall be assessed a late payment fee at a rate of [*] or the maximum rate
permitted by applicable law with respect to such obligations, whichever is less. 

  
 [*] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 

 13. TERMINATION: 
  

	 	a)	Either Party may terminate this Agreement for a material breach by the other Party. A material breach may be encountered if either Party: (a) repudiates or
breaches a [*] of this Agreement; or (b) fails to perform payments or services or deliver goods as provided in this Agreement. A Party may terminate this Agreement under this Section 13 by giving the breaching Party written notice,
specifying the circumstances of the breach, including the provisions of this Agreement that are breached (“Notice”). The breaching Party, if such a breach has indeed occurred, has [*] calendar days from receipt of such Notice
to cure such breach of this Agreement. 

 If the breach has not been cured at the end of the [*] day period
or if the breaching Party is not making [*] to cure such breach, then, upon immediate Notice to the breaching Party, the breaching Party shall be in default and the nonbreaching Party may terminate this Agreement. If the breaching Party is
making [*] to cure such breach up until the end of the [*] day period, the breaching Party shall be granted an additional [*] day period to cure said breach so long as it continues to use [*] to cure such breach. Unless
the termination is on the grounds of a material breach resulting [*], GSL will purchase raw material and intermediates [*]. Otherwise, GSL shall have the right, .but not the obligation, to purchase such raw materials, intermediates and
inventories of the Product pursuant to Section 6 as GSL may determine in its sole discretion. For clarity, but without limitation on other contract damages that may be available in the event of a material breach by a party, in the event the
termination is on grounds of a material breach resulting [*] during the Initial Term, GSL shall pay to AFC [*]. 
  

	 	b)	If either Party becomes bankrupt, the other Party may, with immediate Notice to the first Party, terminate the Agreement with no liabilities whatsoever, subject to
relevant legislation and provisions herein contained. 

  

	 	c)	GSL may terminate this Agreement in whole or in part at any time by giving [*] days written notice to AFC, if GSL, in its sole discretion, determines that
[*], or the FDA or any other regulatory agency of applicable jurisdiction (“Regulatory Authority”) [*] (each, a “Regulatory Termination”). GSL may terminate this Agreement if any Regulatory Authority
that regulates Product or Finished Product [*]. Should GSL terminate this Agreement by a Regulatory Termination: 

  

	 	(i)	AFC will take reasonable measures to cease any ongoing production and limit further expenses associated with such ongoing production; 

 

	 	(ii)	GSL will purchase raw material and intermediates at AFC’s [*]; and 

 

	 	(iii)	AFC will use commercially reasonable efforts to reallocate available capacity at the Facility in order to mitigate its damages under this Agreement; and

  
 [*] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 

	 	d)	Except as otherwise set forth in this Agreement, termination of this Agreement shall not release any Party hereto from any payment, liability or other obligation
existing at the date of termination. 

 14. LIMITED WARRANTY: AFC warrants that Product delivered hereunder
will (i) be manufactured by AFC in accordance with cGMP and other applicable FDA and other rules and regulations of the United States or other countries where Finished Products are marketed, (ii) be manufactured in accordance with the
agreed-upon manufacturing procedures described in the master batch records supplied to GSL in accordance with the provisions of Section 7, as may be modified and disclosed to GSL in accordance with the provisions of Section 7,
(iii) conform to the applicable Specifications set forth in the Contract Manufacturing Manual at the time of Product delivery, and (iv) be provided in compliance with all applicable laws and regulations as more fully set forth in
Section 4 above. GSL’s remedies and AFC’s liability with respect to this warranty are set forth below. This warranty is the only warranty made by AFC with respect to Product delivered hereunder, and may only be modified or amended by
a written instrument signed by a duly authorized officer of AFC and accepted by GSL. THE EXPRESS WARRANTIES SET FORTH IN Section 4 AND THIS Section 14 ARE THE EXCLUSIVE WARRANTIES HEREUNDER, IN LIEU OF ALL OTHER EXPRESS OR IMPLIED
WARRANTIES, INCLUDING, WITHOUT LIMITATION, THE WARRANTIES OF .MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. 
 15. INDEMNIFICATION BY
BUYER: GSL agrees to indemnify, hold harmless, and defend AFC and AFC’s directors, officers, employees and agents, and the directors, officers, employees and agents of any AFC parent, subsidiary, or related company (the “AFC
Indemnitees”) from and against any and all claims, suits, losses, damages, costs, fees, and expenses including without limiting those resulting from or arising out of the [*] or resulting from or arising out of possession, use,
transformation, or sale of the Product by any person other than a AFC Indemnitee, including without limiting the generality of the foregoing any damages, losses, or liabilities whatsoever with respect to death or injury to person or damage to
property, provided that AFC provides GSL with prompt notice of any such claim and the exclusive ability to defend (with the reasonable cooperation of AFC) or settle any such claim, except to the extent that such claims, suits, losses, damages,
costs, fees, or expenses arise or result from any negligent or wrongful act or omission of AFC or any AFC Indemnitee. 
 16. INDEMNIFICATION
BY SELLER: AFC agrees to indemnify, hold harmless and defend GSL and GSL’s directors, officers, employees and agents, and the directors, officers, employees and agents of any GSL parent, subsidiary, or related company (the “GSL
Indemnitees”) from and against any and all claims, suits, losses, damages, costs, reasonable fees, and expenses resulting from or arising out of its manufacture of the Product, or the transportation, storage or use of the Product by AFC before
expiration of the Acceptance Period or GSL’s acceptance of the Product, if earlier, including without limiting the generality of the foregoing any damages, losses, or liabilities whatsoever with respect to death or injury to person or damage to
property, provided that GSL provides AFC with prompt notice of any such claim 

  
 [*] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 

 
and the exclusive ability to defend (with the reasonable cooperation of GSL) or settle any such claim, except to the extent that such claims, suits, losses, damages, costs, fees, or expenses
arises or results from any negligent or wrongful act or omission of GSL or any GSL Indemnitee. 
 17. RECALLS AND ADVERSE EVENTS: If
there is a recall or there are adverse events for Product that may be related to the processing, manufacture or testing of Product by AFC, AFC will provide at GSL’s cost any assistance reasonably requested by GSL in connection with such recall
or adverse events. If Product is recalled due to a breach of the warranty in Section 14, AFC shall be responsible for out-of-pocket expenses reasonably incurred in connection with such recall or seizure including loss of Finished Product,
notification, transportation, destruction expenses and replacement costs, [*]. In any event, [*]. 
 18. NONDISCLOSURE: No
right, express or implied, is granted by this agreement to either party to use in any manner the name of the other or any other trade name or trademark of the other in connection with the performance of the work covered by this agreement. In
addition, each party hereto shall act as an independent contractor and nothing in this agreement shall be construed as to give either party the authority to act for, bind, or commit the other party in any way whatsoever. 

19. INDEPENDENT CONTRACTORS: Each Party hereto will act as an independent contractor and nothing in this Agreement shall be construed as to give
either Party the authority to act for, bind, or commit the other Party in any way whatsoever. 
 20. FORCE MAJEURE: Neither party shall
be liable for failure to perform or for delay in performing any of its obligations under this agreement, if such failure or delay is caused by labor disputes, lack of supply of materials through no fault of such party, an act of God, riot, fire,
explosion, flood, hostilities of war, executive legislation or administrative order, or other conditions reasonably beyond the control of such party, provided that the party experiencing the delay promptly notifies the other party of the delay. In
the event of such cause intervening, this agreement shall be and remain suspended provided that if such cause shall continue for a period of [*] months, the party not subject to the force majeure may [*] from the date of expiration of
such period, [*]. 
 21. REMEDIES: The rights and remedies reserved to GSL in this agreement shall be cumulative, and in
addition to all other or further remedies provided in law or equity. 
 22. NONASSIGNABILITY: Neither party may assign or transfer
this agreement or any rights or obligations hereunder without the prior written consent of the other party, except that GSL may make such an assignment or transfer without AFC’s consent if such assignment or transfer is to an Affiliate or
successor to substantially all of the business of GSL, whether in a merger, sale of stock, sale of assets, or other similar transaction. Any assignment or transfer or attempted assignment or transfer by either party in violation of the terms of this
Section 22 shall be null and void and of no legal effect. In the case of any permitted assignment or transfer of or under this agreement, this agreement shall be binding upon, and inure to the benefit of, the

  
 [*] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 

 
successors, executors, heirs, representatives, administrators, and assigns of the Parties hereto. 
 23. GOVERNING LAW: This agreement is to be construed according to the laws of the State of [*], as such laws are applied to contracts made in [*] between [*] residents, and
excluding the United Nations’ Convention on Contracts for the Sale of Goods. 
 24. SEVERABILITY: In the event any term of this
agreement is held to be invalid or unenforceable under any statute, regulation, ordinance, executive agreement or other rule of law, such term shall be deemed modified or deleted, but only to the extent necessary to comply with such statute,
regulation, ordinance, agreement or rule, and the valid or enforceable portion thereof and the remaining terms of this agreement will remain in full force and effect, unless the invalid or unenforceable provisions are of such essential importance to
this agreement that it is reasonably assumed that the Parties would not have entered into this agreement without the invalid terms. 
 25.
WAREHOUSING: Subject to the availability of space and storage conditions, AFC will store Product for GSL upon written request by GSL no later than [*] days after GSL’s receipt of the Certificate of Compliance and Certificate of
Analysis. GSL’s written request must state that GSL requests AFC not to ship the Product, the business reason for delay and also provide an estimated revised delivery date for the Product. The payment terms included in Section 12 are
unchanged. GSL agrees to pay AFC storage charges for the Product at prevailing rates for the storage of similar Products under similar conditions. However, the negotiated price of the Product includes storage of the Product for up to [*] at
AFC’s facility [*] to GSL. For Product stored by AFC for GSL, delivery of Product will be considered to have occurred when the Product is placed into storage by AFC. The provisions of Section 10 related to transfer of title and risk
of loss for the Product remain in effect. AFC will store the Product in accordance with cGMP and other applicable FDA and other rules and regulations of the United States. AFC will store Product segregated from other stored items in such a condition
that Product is “ready to ship” with minimal delay. Product in storage at AFC will be shipped to GSL on a first-in, first-out (FIFO) basis. [*] shall maintain appropriate insurance as far as AFC’s custodial responsibilities
with respect to the Product owned by GSL and stored at AFC’s facility. Upon GSL’s written request, AFC will provide GSL with a certificate of insurance verifying that AFC maintains appropriate insurance as far as AFC’s custodial
responsibilities with respect to Product owned by GSL and stored at AFC’s facility. Upon AFC’s written request, GSL will provide AFC with a certificate of insurance verifying that GSL maintains property insurance for Product that it owns
that is stored at AFC’s facility. Upon GSL’s written request, AFC will remove a representative sample from any Product owned by GSL and stored at AFC’s facility and forward that sample to GSL. 

26. NOTICES: All notices under this Agreement shall be in writing and shall be delivered personally, sent for next day delivery by internationally
recognized courier service or transmitted by facsimile (transmission confirmed), with confirmation by next day delivery by an 

  
 [*] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 

 
internationally recognized courier service, to the following addresses and facsimiles of the respective Parties or such other address or facsimile as is notified pursuant to this Section 26:

  

			
	 If to GSL:
	 	With a copy to:
		
	 Gilead Sciences Limited/ 
 [*]
	 	 Gilead Sciences, Inc.
 333
Lakeside Drive
 Foster City, CA 94404

USA
 Attention: Senior Director,
Chemical
 Manufacturing
 Facsimile:
+[*]

		
	 If to AFC:
	 	With a copy to:
		
	 Ampac Fine Chemicals/ 
 [*]
	 	 Ampac Fine Chemicals LLC

Highway 50 & Hazel Avenue
 Rancho Cordova, CA
95670
 USA
 Attention: Vice President,
Product Management
 Facsimile: +[*]

 27. CONFIDENTIALITY: 
  

	 	a)	 “Confidential Information” means with respect to GSL confidential or proprietary information of GSL or any of its Affiliates either
disclosed in oral, written or other tangible form or otherwise learned by AFC from GSL related to the manufacture of Product under (i) these terms and any purchase order related thereto, (ii) the Tenofovir DF Purchase Order Terms and
Conditions dated as of June 12, 2002 and August 9, 2007, as amended, and any purchase order related thereto, and (iii) the Gilead Sciences, Inc. Confidential Disclosure Agreement dated March 4, 2000 (collectively, the
“Documents”) that should reasonably be believed to be confidential or proprietary to GSL or any of its Affiliates, including but not limited to information directly related to the Product or the research, development, preclinical
and clinical programs, data and results; pharmaceutical or biologic candidates and products; inventions, works of authorship, trade secrets, processes, conceptions, formulas, patents, patent applications, and licenses; inventions; business, product,
marketing, sales, scientific and technical strategies, programs and results, including costs and prices; suppliers, manufacturers, customers, market data, personnel, and consultants of GSL or any of its Affiliates; and other confidential or
proprietary matters directly related to GSL or any of its Affiliates, including work done under any purchase order. “Confidential Information” means with 

  
 [*] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 

	 	 
respect to AFC any information which is not Confidential Information of GSL and is confidential or proprietary information of AFC or any of its Affiliates or customers either disclosed in oral,
written or other tangible form or otherwise learned by GSL from AFC that should reasonably be believed to be confidential or proprietary to AFC or any of its customers or Affiliates, including but not limited to information directly related to the
contract manufacturing business of AFC; works of authorship, trade secrets, processes, conceptions, formulas, patents, patent applications, and licenses; inventions; business, product, marketing, sales, scientific and technical strategies, programs
and results, including costs and prices; suppliers, customers, market data, personnel, and consultants of AFC or any of its Affiliates; and other confidential or proprietary matters directly related to AFC or any of its Affiliates, including work
done by AFC for other customers. 

  

	 	b)	“Discloser” shall mean the party, whether GSL or AFC, disclosing its Confidential Information to the other party. “Recipient” shall
mean the party, whether GSL or AFC, receiving Confidential Information of the other party. 

  

	 	c)	“Affiliate” shall mean any corporation or other business entity controlled by, controlling, or under common control with the respective party. For this
purpose, “control” of a party, corporation or other business entity (including controlled by, controlling, or under common control with) shall mean the following (i) direct or indirect ownership or control of at least 50% of the
issued and voting capital by the respective party, or (ii) possession of the power to direct or cause the direction of the management and policies of an entity, whether by ownership of voting stock, by contract, or otherwise.

  

	 	d)	Subject to Section 27(f), until [*], Recipient: 

  

	 	(i)	shall not use Confidential Information of Discloser except for the purpose of carrying out obligations contemplated by the Documents; 

 

	 	(ii)	will hold Confidential Information of Discloser in strictest confidence and shall not disclose Confidential Information of Discloser to third parties, except for its
employees or agents who require Confidential Information of Discloser in order to carry out obligations under the Documents and who are subject to binding obligations of confidentiality and restricted use at least as protective as those of this
Section 27; 

  

	 	(iii)	will protect the confidentiality of Confidential Information of Discloser using at least the same level of efforts and measures used to protect its own confidential
information, and at least commercially reasonable efforts and measures, including without limitation limiting access to Confidential Information commensurate with carrying out obligations contemplated by the Documents and keeping adequate records of
those with access to Confidential Information of Discloser and of all uses or dispositions of Confidential Information of Discloser; and 

  
 [*] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 

	 	(iv)	will notify Discloser as promptly as practicable of any unauthorized use or disclosure of Confidential Information by employees or agents of which Recipient becomes
aware. 

  

	 	e)	Recipient’s obligations under Section 27(d) shall not apply to any Confidential Information that: 

 

	 	(i)	Recipient knew prior to learning it under the Documents, as demonstrated by written records predating the date it was learned under the Documents;

  

	 	(ii)	is now, or becomes in the future, publicly available other than by an act or omission of Discloser; 

 

	 	(iii)	a third party discloses to Recipient, without any confidentiality obligations, and without any breach of any direct or indirect obligation of confidentiality to
Discloser, as shown by Recipient’s written records contemporaneous with such third party disclosure; or 

  

	 	(iv)	Recipient independently develops without use of or reference to Confidential Information of Discloser, as demonstrated by Recipient’s independent written records
contemporaneous with such development. 

  

	 	f)	Notwithstanding other provisions of this Section 27, Recipient may disclose Confidential Information of Discloser to the extent and to the persons or entities
required under applicable governmental law, rule, regulation or order, provided that Recipient (i) first gives prompt written notice of such disclosure requirement to Discloser so as to enable Discloser to seek any limitations on or exemptions
from such disclosure requirement and (ii) reasonably cooperates at Discloser’s request and expense in any such efforts by Discloser. 

  

	 	g)	Upon termination of these terms or Discloser’s request for any reason, Recipient will (i) immediately cease all use of all Confidential Information of
Discloser disclosed hereunder or under the other Documents and (ii) promptly return to Discloser or, if instructed by Discloser, destroy all such Confidential Information of Discloser, including any copies, extracts, summaries, or derivative
works containing such Confidential Information of Discloser, and certify in writing to Discloser the completion of such return and/or destruction, provided, however, that Recipient may retain one copy in its legal archives solely for the purpose of
monitoring its surviving obligations under the Documents. 

  

	 	h)	 Discloser retains all right, title and interest in and to Confidential Information except to the extent otherwise provided by Section 8. This
Section 27 gives Recipient no right or license, by implication or otherwise, to any Confidential Information of Discloser or any intellectual property or other rights owned by or licensed to Discloser except the right to use Confidential
Information solely for performance of obligations under the Documents 

  
 [*] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 

	 	 
and as otherwise specifically provided in Section 8. Recipient may freely transfer, disclose and/or use Recipient’s Confidential Information for its or others’ purposes.

  

	 	i)	Recipient acknowledges that any actual or threatened breach of this Section 27 may cause Discloser immediate and irreparable harm that cannot be adequately
compensated by monetary damages, and it therefore agrees that Discloser shall not be required to demonstrate irreparable harm in order to seek or obtain injunctive relief for actual or threatened breach of these terms. In addition to any injunctive
relief, Discloser may seek any other remedies available to it at law or in equity. 

 28. ENTIRE AGREEMENT; AMENDMENTS:
This agreement together with the attachments, exhibits, or supplements specifically referenced in this agreement, constitutes the entire, final, complete, and exclusive agreement between the Parties and supersedes all previous agreements (including
specifically the Tenofovir DF Purchase Order Terms and Conditions dated June 12, 2002, as amended by Amendment No. 1 and Amendment No. 2, the Tenofovir DF purchase order terms and conditions dated August 9, 2007 (CD-07-0200), and
the Gilead Sciences, Inc. Confidential Disclosure Agreement dated March 4, 2002)) or representations, written or oral, with respect to the subject matter of this agreement. This agreement may not be modified, amended, waived, discharged, or
terminated orally, but only by an instrument in writing signed by a duly authorized representative of each party. SUBJECT TO SUCH AMENDMENT, THE TERMS AND CONDITIONS SET FORTH HEREIN CONSTITUTE THE FINAL COMPLETE, EXCLUSIVE, AND ENTIRE AGREEMENT
BETWEEN GSL AND AFC WITH RESPECT TO THE SUBJECT MATTER HEREOF. ANY TERM OR CONDITION IN ANY AGREEMENT, CONFIRMATION, OR OTHER DOCUMENT FURNISHED BY GSL OR AFC WHICH IS IN ANY WAY INCONSISTENT WITH THE TERMS SET FORTH HEREIN IS HEREBY EXPRESSLY
REJECTED. 
 29. INSURANCE: Each Party will maintain at is own cost insurance policies, which may be by means of self-insurance, with
respect to its activities and obligations under this Agreement that are commercially reasonable as to terms, coverage and coverage limits in view of the scope of such Party’s activities and obligations under this Agreement. [*].
At the other Party’s request, each Party will supply certificates of insurance evidencing such coverages. 
 30. SURVIVAL: The
provisions of Sections 8, 14, 15, 16, 17, 18, 22, 23, 24, and 27 shall survive the termination or expiration of this Agreement. 

  
 [*] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 

 The Parties have entered into this Agreement as of the Effective Date by their duly authorized
representatives. 
  

			
	 GILEAD SCIENCES LIMITED

		
	 By:
	 	 /s/ John F. Milligan

		
	 Name:
	 	 John F. Milligan, Ph.D. Ph.D.

		
	 Date:
	 	 November 8, 2010

		
	 Title:
	 	 Director

	
	 AMPAC FINE CHEMICALS LLC

		
	 By:
	 	 /s/ Richard Beatty

		
	 Name:
	 	 Richard Beatty

		
	 Date:
	 	 November 8, 2010

		
	 Title:
	 	 Vice President

  
 [*] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 

 Exhibit A 
 Product Minimum Purchase Quantities 
 The table below sets forth GSL’s minimum Product
purchase obligations for the stated calendar years for Product for commercial use. 
 CASE A: 

 

									
	 	  	2011	 	  	2012	  	2013
	 [*] Metric Tons (minimum purchase obligation)
	  	 	NA	  	  	[*]/kg	  	[*]/kg
	 [*] Metric Tons* (optional)
	  	 	NA	  	  	[*]kg*	  	[*]/kg*
	 [*] Metric Tons
	  	 	[*]/kg	  	  	NA	  	NA

  

	*	Note: Pricing is for optional incremental TDF volumes, which would be in addition to the [*]. [*]. 

Price shall be based upon the expected acquisition costs of the key raw materials below. Variance from these acquisitions costs shall be invoiced or
credited to GSL as [*] or at the completion of a GSL Purchase Order on an annual basis. 
  

					
	 Key Raw Material
	 	 2011 Acquisition Cost Base

($USD/kg)
	 	 2012/2013 Acquisition Cost

Base ($USD/kg)

	 [*]
	 	[*]	 	[*]
	 [*]
	 	[*]	 	[*]
	 [*]
	 	[*]	 	[*]
	 [*]
	 	[*]	 	[*]
	 [*]
	 	[*]	 	[*]

  
 [*] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00185-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00185-of-00352.parquet"}]]